OP0050 The treatment gap after fracture in osteoporosis patients in sweden

Background In Sweden, ∼50% of women and ∼25% of men are expected to suffer an osteoporosis (OP)-related fracture (Fx) during their lifetime, and hip Fx incidence in Sweden is one of the highest worldwide. Despite this, nationally only 12% of patients with Fx are prescribed an OP treatment following Fx. 1 Understanding the reasons for the marked under-treatment of patients with Fx may provide insights into how to improve deficiencies in the management of OP. Objectives To assess rates of OP treatment initiation within 1 year ( Methods Patients aged ≥50 yrs with any type of Fx were identified from Swedish national registers between 2006–2012 and followed from time of first Fx. Patients who were treatment-naive at the time of first Fx were included in the analysis. Here, we report OP treatment initiation Results 258,827 treatment-naive patients with a first Fx (68% female; mean age 72.7 [SD 12.9] yrs) were included. Overall, 6.6% of patients initiated OP treatment Conclusions This study confirms the large treatment gap in OP treatment initiation following a first Fx in Sweden; rate of OP treatment initiation was below the post-Fx treatment initiation rate goal of 30% and also lower than the 12% published national indicator for treatment exposure (2015). 1 The proportion of patients initiating OP treatment appears to be somewhat influenced by gender, age, Fx type, GC use, rheumatic disease, dependency and dementia; nevertheless, treatment initiation rates were low. These data highlight the need for significant efforts to improve OP management post Fx in Sweden. References Swedish Association of Local Authorities and Regions (SKL) and The National Board of Health and Welfare (2015) Oppna Jamforelser 2015, Halso- och sjukvard vid kroniska sjukdomar. Acknowledgements Funded by UCB Pharma. Disclosure of Interest A. Spangeus Consultant for: Amgen, Speakers bureau: Amgen; Eli Lilly, K. Akesson Grant/research support from: Amgen, Eli Lilly, O. Ljunggren Grant/research support from: Amgen, Eli Lilly, J. Banefelt Consultant for: Quantify Research, funded by UCB to conduct this study, Employee of: Quantify Research, funded by UCB to conduct this study, L. Karlsson Consultant for: Quantify Research, funded by UCB to conduct this study, Employee of: Quantify Research, funded by UCB to conduct this study, G. Ortsater Consultant for: Quantify Research, funded by UCB to conduct this study, Employee of: Quantify Research, funded by UCB to conduct this study, C. Libanati Shareholder of: UCB Pharma, Employee of: UCB Pharma, E. Toth Shareholder of: UCB Pharma, Employee of: UCB Pharma, O. Strom Grant/research support from: Quantify Research, funded by UCB to conduct this study, Consultant for: Quantify Research, funded by UCB to conduct this study